Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
5 FDA Decisions to Watch in the First Quarter of 2026
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Biotech in 2025: A Retrospective
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
3 Trends Shaping the GLP-1 Landscape
Madrigal Eyes Combination MASH Therapy with Pfizer Deal
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
New CagriSema Data Show Improvement over Semaglutide
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Office CMBS Delinquency Rate Spikes to Record 12.3%, Much Worse than Financial Crisis Meltdown Peak
Labiotech’s 15 Biopharma Companies to Watch in 2026
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Aspect Biosystems and Novo Nordisk – Enter New Phase of Partnership to Develop Curative Medicines for Diabetes
GLP-1 Drugs Linked to Pancreatitis, Gallbladder Problems
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
CMS's Medicare Price Negotiations Start Round Three
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
Ventus Therapeutics – Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus
Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Embattled Novo Nordisk Considers Buying a Monthly GLP-1 to Bolster Portfolio
FDA Asks Lilly, Novo to Remove Suicide Warnings From GLP-1 Labels
5 Questions Facing Biopharma in 2026
Should Drug Companies Be Advertising to Consumers?
Hims & Hers Plans to Acquire Eucalyptus for $1.15B
11 Companies Hiring Manufacturing Professionals Now
The New Wave of Protein Is for the Girls
The New Gold Rush in Brain Science
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Slides 14% as Early Q4 Results Predict Sales Decline for 2026
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
Hims & Hers Stock Crashes After FDA Announces Plans to Take 'Decisive Steps' Against GLP-1 Compounds
Novo Nordisk Sues Hims over Wegovy Patent Infringement, Considers Seeking 'Hundreds of Millions' In Damages
CHMP Opposes Lilly’s Mounjaro in Heart Failure, Backs Novo’s Kayshild
EToro Sponsors Djurgårdens IF as Nordic Stock Access Expands for Retail Clients
STAT+: Novo Strikes Deal for Diabetes Cell Therapies
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions